NASA's InSight Survived the Trip to Mars ー Now Comes the Wait for Results
*By Conor White*
The Curiosity rover is no longer alone on Mars.
NASA's InSight lander successfully touched down on the Red Planet Monday afternoon, but spectators will have months to wait before any results arrive.
"It's a 26-month mission," said Sarah Lewin, an associate editor at Space.com said. The first results from InSight's experiments are expected sometime in the spring.
InSight marks NASA's first mission to Mars since Curiosity began its journey in 2011. The launch was originally scheduled for 2016 before officials discovered a leak in the rocket's vacuum chamber. As a result, InSight missed its launch window. The delay and necessary repairs added almost $154 million to the mission's price tag, bringing it to a total cost of $814 million.
And even those years of planning didn't guarantee a success.
"Mars missions have like a 40 percent success rate across the world," Lewin said. "NASA is a little bit higher, so there was a definite chance it wouldn't work."
Now that it has safely landed, the probe will be responsible for drilling into Mars ー largely to determine the planet's composition. The robot will also monitor the planet for "Marsquakes."
"We've put a lot of things on Mars that are either orbiters, which are looking down on it, or rovers like Curiosity exploring the surface, but we really don't know what's going on inside," Lewin said.
Virgin Galactic is reporting an increase in demand for commercial space flights after seeing a boost in ticket sales, raising the price for a seat on a shuttle to $450,000. The company said they now have 700 customers.
Jill Wagner and Baker Machado break down the state of the Opioid Crisis in the U.S. The CDC reported a 30% increase in overdose deaths from 2020 to 2021, but in recent months pharmaceutical companies have drastically raised the price of Naloxone or 'Narcan,' affecting the response of community harm prevention groups.
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Jill and Carlo discuss the scenes of joy at American airports as borders reopen, another tool in the Covid toolbox, the latest in the Astroworld crowd crush tragedy and more.
The Biden Administration's mandate for COVID vaccinations by large employers has been put on hold by federal courts as GOP-led states and some businesses push back on the order's legality. Jonathan Adler, a law professor at Case Western Reserve University, joined Cheddar to discuss the legal challenges to implementing such mandates through OSHA (Occupational Safety and Health Administration). "Certainly expanding vaccinations is a good thing, and as vaccination rates go up that's better for all of us," Adler said. "But there are some legal questions about whether or not it's appropriate to use a law about occupational safety and health as the means to do that."
Dr. Nasia Safdar, Doctor at UW Madison, joined Wake Up With Cheddar to discuss the implications of Merck sharing its antiviral pill, which has been shown in early trials to cut hospitalizations and deaths by half, with poorer nations around the globe.
Dr. Robert Frenck, an infectious disease specialist at Cincinnati Children's Hospital, joined Cheddar to talk about the significance of children ages 5-11 being authorized to receive COVID-19 vaccinations. He also discussed schools being cleared to administer vaccines and noted the importance of meeting people where they are rather than forcing them to find the shots. Frenck also said he expects that children under 5 years old will begin getting vaccinations sometime in spring.
A CDC advisory committee as unanimously voted to recommend the Pfizer Covid-19 vaccine in children ages 5 to 11. Dr. Amesh Adalja, Infectious Disease Specialist and Senior Scholar at Johns Hopkins Center for Health Security, joined Cheddar News to discuss.
A Freitag pod with Carlo and Baker, talking about the upcoming federal vax-or-test deadline, the most shocking upset of this week's elections, an incredible story of selflessness and Love, Hate, Ate.
